|
|
Post by LosingMyBullishness on Jan 19, 2016 11:26:02 GMT -5
Today's price action also has to do with a GS price downgrade before the open to $0.25. The headline was also then shared via Bloomberg by arie Shapira who seems to be the shorts mouthpiece via Bloomberg. Every time there was a Jason krp downgrade arie would be spreading the news. They just won't give up and management still is mum. Hope we get something soon by way of good news. Very tiring to be a mnkd investor. If true, one has to wonder how many stocks GS covers on which it has a $0.25 price target. More to the point, how many penny stocks does GS cover?  Surely, they can find better stocks to which to assign their highly paid, or should I say, overpaid analysts. It has been pretty awkward when GS started to cover tiny MNKD. GS had a agenda. |
|
|
|
Post by coo2002coo on Jan 19, 2016 11:28:24 GMT -5
Today's price action also has to do with a GS price downgrade before the open to $0.25. The headline was also then shared via Bloomberg by arie Shapira who seems to be the shorts mouthpiece via Bloomberg. Every time there was a Jason krp downgrade arie would be spreading the news. They just won't give up and management still is mum. Hope we get something soon by way of good news. Very tiring to be a mnkd investor. If true, one has to wonder how many stocks GS covers on which it has a $0.25 price target. More to the point, how many penny stocks does GS cover? Surely, they can find better stocks to which to assign their highly paid, or should I say, overpaid analysts. It also provide an opportunity for the shorts to shake the weak hands easily when no announcement of any deals this week b/c longs have expected announcement was to be released within a few days after Jan 13! |
|
|
|
Post by peppy on Jan 19, 2016 11:31:38 GMT -5
Afrezza price cut announcement needed stat in my opinion. If nothing else, smacks SNY in the back pocket. There was some discussion of that in another thread. Sanofi is still our sales force, until april 4 as near as I can tell. Mannkind can price afrezza where ever it wants now. what was not clear, can mnkd mandate sanofi's sales force sell Afrezza at a price mannkind sets? Mnkd seemed to have the option of suspending sanofi sales team.
"SNY lost exclusive rights to market Afrezza when they gave notice. SNY is no longer calling all the shots on marketing. MNKD is free to market Afrezza how they please."
12.3 Additional Sanofi Termination Rights.
(a) If, at any time on or after January 1, 2016, Sanofi determines in good faith that Commercialization of Product is no longer economically viable in the United States, then Sanofi may terminate this Agreement in its entirety upon delivery of at least ninety (90) days’ prior written notice to MannKind
12.4 Additional MannKind Termination Right. MannKind shall have the right to terminate this Agreement immediately upon written notice to Sanofi if Sanofi or any of its Affiliates or sublicensees directly, or indirectly through any Third Party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of,
www.sec.gov/Archives/edgar/data/899460/000119312514406347/d783199dex101.htm
Read more: mnkd.proboards.com/thread/4952/price-reduction#ixzz3xhzTRgEP
|
|
|
|
Post by longinvstr on Jan 19, 2016 11:56:39 GMT -5
If true, one has to wonder how many stocks GS covers on which it has a $0.25 price target. More to the point, how many penny stocks does GS cover? Surely, they can find better stocks to which to assign their highly paid, or should I say, overpaid analysts. It has been pretty awkward when GS started to cover tiny MNKD. GS had a agenda.Yes, as Cerberus, the three-headed dog, guarding BP's gate. The odds are sooo unfavorable. To stay long, one has to believe that good will triumph evil |
|
|
|
Post by peppy on Jan 19, 2016 12:17:56 GMT -5
remember last Thursday when board members commented on the trading being with a penny for hours...
looks like the same price action now.
An order to cover at this price my guess.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 19, 2016 12:22:17 GMT -5
I would like to know what GSCO has to do with the current state of scripts and current technosphere pipe line
|
|
|
|
Post by nuklerfizzacist on Jan 19, 2016 12:22:42 GMT -5
It has been pretty awkward when GS started to cover tiny MNKD. GS had a agenda.Yes, as Cerberus, the three-headed dog, guarding BP's gate. The odds are sooo unfavorable. To stay long, one has to believe that good will triumph evil Your assessment pretty much represents my position as well. GS has an agenda. Tough place to be, but here I am cheering for the good guys. |
|
|
|
Post by coo2002coo on Jan 19, 2016 12:23:12 GMT -5
Really hate to say that share price has become the indication of MNKD new CEO's ability to execute deals, rather than to provide transparency. Matt should stay focus to close deals than to calm investor by letting them (& your competitors) know what he is doing.
|
|
|
|
Post by kbrion77 on Jan 19, 2016 12:26:12 GMT -5
Really hate to say that share price has become the indication of MNKD new CEO's ability to execute deals, rather than to provide transparency. Matt should stay focus to close deals than to calm investor by letting them (& your competitors) know what he is doing. He's been CEO for 2 weeks and he already has an inability to close deals? If it's May and they still haven't signed a Technosphere partner then I would say your comment could be used then. |
|
|
|
Post by nuklerfizzacist on Jan 19, 2016 12:29:56 GMT -5
I would like to know what GSCO has to do with the current state of scripts and current technosphere pipe line You're right, gsco is a totally above board company...I've never heard of any indiscretions on their part...ever. |
|
|
|
Post by coo2002coo on Jan 19, 2016 12:37:05 GMT -5
Really hate to say that share price has become the indication of MNKD new CEO's ability to execute deals, rather than to provide transparency. Matt should stay focus to close deals than to calm investor by letting them (& your competitors) know what he is doing. He's been CEO for 2 weeks and he already has an inability to close deals? If it's May and they still haven't signed a Technosphere partner then I would say your comment could be used then. Matt has attended the past call conferences as CFO but acted like an acting CEO. He has been with the company for years and should know the company inside out. He definitely has the positions and influence as to most decisions by the former CEO. I just feel awkward that Matt's talk about very close to concluding deals in the near future on Jan 13 has demonstrated his inexperience in business dealings and handling crisis. I mean you do not get mercy from potential partners when they know you'r in desperate position to partner with them, do you? |
|
|
|
Post by greg on Jan 19, 2016 12:51:32 GMT -5
A little perspective might be useful....
Given the never ending nonsense from the dark side, the price of this stock is going to go up and down a dime or two on a regular basis. Big on a percentage basis, but hardly grounds to panic. Certainly not reason enough to cause panic with alarming titles.
As things stand, either the company will come up with some good news, and it won't take much, or it won't. A technosphere deal or two, a regional partner or two, the establishment of a diabetes care store or two, a decent go-away cash payment from SNY, etc, and the stock goes up many percentage points. On the other hand, if nothing materializes sometime reasonably soon, than losing a dime or two today doesn't mean much.
|
|
|
|
Post by peppy on Jan 19, 2016 13:08:36 GMT -5
A little perspective might be useful....Given the never ending nonsense from the dark side, the price of this stock is going to go up and down a dime or two on a regular basis. Big on a percentage basis, but hardly grounds to panic. Certainly not reason enough to cause panic with alarming titles.
As things stand, either the company will come up with some good news, and it won't take much, or it won't. A technosphere deal or two, a regional partner or two, the establishment of a diabetes care store or two, a decent go-away cash payment from SNY, etc, and the stock goes up many percentage points. On the other hand, if nothing materializes sometime reasonably soon, than losing a dime or two today doesn't mean much. Alrighty then screencast.com/t/i8XUTVL3y
|
|
|
|
Post by liane on Jan 19, 2016 13:09:19 GMT -5
I would like to know what GSCO has to do with the current state of scripts and current technosphere pipe line You're right, gsco is a totally above board company...I've never heard of any indiscretions on their part...ever.    |
|
|
|
Post by compound26 on Jan 19, 2016 13:12:33 GMT -5
Matt was announced as CEO as of 11th Jan. So he has been CEO basically for one week.
Since he already did the JPM presentation on 13 Jan., it is reasonable that the company does not have or announce any news within a few days of such presentation. It is also expected that Mannkind is all over the place working on executing or fleshing out some of the plans Matt discussed in the JPM presentation.
I recall Matt mentioned that he may do a conference call with investors before the next quarterly conference call.
I expect the next conference call to be sometime around 10 Feb.
Since Matt made the JPM presentation on 13 Jan. and the next quarterly conference will be around 10 Feb., it appears likely that, if Matt does do a conference call before the next quarterly conference, such a call will be scheduled around the end of Jan.
My guess is that 29 Jan. (Friday, which is 10 days from today) maybe the date for such a call. If Matt does hold such a call, he may be able to announce a TS deal or other news on such conference call.
If not, we will hear some news by the next quarterly conference call (around 10 Feb.), which is three weeks from today.
|
|
Surely, they can find better stocks to which to assign their highly paid, or should I say, overpaid analysts. 
